Rozzini_2007_Am.J.Alzheimers.Dis.Other.Demen_22_42

Reference

Title : Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study - Rozzini_2007_Am.J.Alzheimers.Dis.Other.Demen_22_42
Author(s) : Rozzini L , Chilovi BV , Bertoletti E , Conti M , Delrio I , Trabucchi M , Padovani A
Ref : Am J Alzheimers Dis Other Demen , 22 :42 , 2007
Abstract :

Cholinesterase inhibitors (ChEIs) are effective in improving cognition and behavior in patients affected by Alzheimer's disease (AD) as well as by Lewy bodies dementia (DLB). The authors compared the effect of rivastigmine in the treatment of cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) in 30 AD and in 30 DLB patients. At baseline, DLB compared to AD patients showed a greater number of extrapyramidal symptoms (P < .005) and were similar regarding cognitive symptoms and BPSD. After treatment, both groups showed a comparable cognitive and psycho-behavioral improvement. A significant difference between AD and DLB patients was found for hallucinations (P < .002). Rivastigmine produces comparable cognitive benefits in patients with DLB and AD and also a significant improvement of behavioral disorders. These findings support the view that ChEIs should be considered a first-line treatment of the cognitive and psycho-behavioral symptoms of both AD and DLB.

PubMedSearch : Rozzini_2007_Am.J.Alzheimers.Dis.Other.Demen_22_42
PubMedID: 17534001

Related information

Citations formats

Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padovani A (2007)
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study
Am J Alzheimers Dis Other Demen 22 :42

Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padovani A (2007)
Am J Alzheimers Dis Other Demen 22 :42